JA Wagner

2.3k total citations
27 papers, 1.7k citations indexed

About

JA Wagner is a scholar working on Molecular Biology, Economics and Econometrics and Statistics and Probability. According to data from OpenAlex, JA Wagner has authored 27 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Economics and Econometrics and 5 papers in Statistics and Probability. Recurrent topics in JA Wagner's work include Statistical Methods in Clinical Trials (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Receptor Mechanisms and Signaling (4 papers). JA Wagner is often cited by papers focused on Statistical Methods in Clinical Trials (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Receptor Mechanisms and Signaling (4 papers). JA Wagner collaborates with scholars based in United States, Belgium and United Kingdom. JA Wagner's co-authors include Solomon H. Snyder, Baldomero M. Olivera, Ian J. Reynolds, R. J. Miller, Stanley A. Thayer, Chris Webster, A M Snowman, Arpita Biswas, B.M. Olivera and SH Snyder and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Neuroscience and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

JA Wagner

27 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
JA Wagner United States 19 782 377 307 274 200 27 1.7k
Ronald Gieschke Switzerland 21 304 0.4× 120 0.3× 277 0.9× 150 0.5× 38 0.2× 47 1.5k
David Hreniuk United States 16 546 0.7× 79 0.2× 117 0.4× 219 0.8× 222 1.1× 28 1.2k
Kyung‐Hoon Lee South Korea 22 339 0.4× 120 0.3× 157 0.5× 105 0.4× 62 0.3× 73 1.4k
Paola Borgiani Italy 31 846 1.1× 59 0.2× 173 0.6× 320 1.2× 129 0.6× 137 2.6k
Ewa Ehrenborg Sweden 34 1.5k 2.0× 44 0.1× 114 0.4× 70 0.3× 724 3.6× 84 3.4k
Anthony G.W. Norden United Kingdom 31 1.2k 1.6× 36 0.1× 88 0.3× 195 0.7× 185 0.9× 66 3.0k
R Stoltz United States 19 337 0.4× 145 0.4× 62 0.2× 138 0.5× 150 0.8× 31 1.2k
Donna J. Buckley United States 26 713 0.9× 61 0.2× 548 1.8× 96 0.4× 22 0.1× 58 1.8k
Cinzia Ciccacci Italy 25 492 0.6× 43 0.1× 115 0.4× 90 0.3× 111 0.6× 78 1.6k
Aiping Zhang China 24 503 0.6× 64 0.2× 220 0.7× 72 0.3× 139 0.7× 101 1.8k

Countries citing papers authored by JA Wagner

Since Specialization
Citations

This map shows the geographic impact of JA Wagner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JA Wagner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JA Wagner more than expected).

Fields of papers citing papers by JA Wagner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JA Wagner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JA Wagner. The network helps show where JA Wagner may publish in the future.

Co-authorship network of co-authors of JA Wagner

This figure shows the co-authorship network connecting the top 25 collaborators of JA Wagner. A scholar is included among the top collaborators of JA Wagner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JA Wagner. JA Wagner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wagner, JA, et al.. (2015). Implications of the Institute of Medicine Report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Clinical Pharmacology & Therapeutics. 98(1). 12–15. 13 indexed citations
2.
Wagner, JA, et al.. (2014). First‐to‐Patent Does not Predict First‐ or Best‐in‐Class: Analysis of Approved Small Molecule vs. Biologic Drugs. Clinical Pharmacology & Therapeutics. 97(1). 19–21. 1 indexed citations
3.
Momper, Jeremiah D. & JA Wagner. (2013). Therapeutic Drug Monitoring as a Component of Personalized Medicine: Applications in Pediatric Drug Development. Clinical Pharmacology & Therapeutics. 95(2). 138–140. 22 indexed citations
4.
Caro, Luzelena, et al.. (2013). Pharmacokinetic Interaction of HCV Protease Inhibitor MK-5172 and Ritonavir in Healthy subjects. 9(2). 55–56. 8 indexed citations
5.
Kennedy, David O., Nicole Lewis, Tine Laethem, et al.. (2012). The single dose pharmacokinetic (PK) and pharmacodynamic (PD) profiles of suvorexant (MK-4305); a dual orexin receptor antagonist, in healthy male subjects. Ghent University Academic Bibliography (Ghent University). 8 indexed citations
6.
Iwamoto, Marian, Raffaele Iannone, & JA Wagner. (2012). Use of Healthy Volunteers Drives Clinical Oncology Drug Development Decision Making. Clinical Pharmacology & Therapeutics. 92(5). 571–574. 9 indexed citations
7.
Reitman, Marc L., Xiaoyan Chu, Xiaoxin Cai, et al.. (2010). Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug–Drug Interaction Trial Design. Clinical Pharmacology & Therapeutics. 89(2). 234–242. 133 indexed citations
8.
Jin, Bo, Sheila Breidinger, Steven D. Young, et al.. (2009). Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms. Clinical Pharmacology & Therapeutics. 85(6). 623–627. 76 indexed citations
9.
Amakye, Dereck D., Wen Dai, Cynthia J. Girman, et al.. (2009). The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development. Clinical Pharmacology & Therapeutics. 86(1). 32–43. 41 indexed citations
10.
Stoch, S. Aubrey, Stefan Zajic, Julie A. Stone, et al.. (2009). Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies. Clinical Pharmacology & Therapeutics. 86(2). 175–182. 124 indexed citations
11.
Wagner, JA, et al.. (2009). Drug Development Perspective on Pharmacokinetic Studies of New Drugs in Patients With Renal Impairment. Clinical Pharmacology & Therapeutics. 86(5). 557–561. 26 indexed citations
12.
Poland, Bill, et al.. (2009). The Clinical Utility Index as a Practical Multiattribute Approach to Drug Development Decisions. Clinical Pharmacology & Therapeutics. 86(1). 105–108. 25 indexed citations
13.
Iwamoto, Marian, Larissa Wenning, Sheila Breidinger, et al.. (2008). Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval. The Journal of Clinical Pharmacology. 48(6). 726–733. 39 indexed citations
14.
Ghosh, Kalyan, et al.. (2008). The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies. Clinical Pharmacology & Therapeutics. 84(4). 475–480. 130 indexed citations
15.
Iwamoto, Marian, Martine E. Laethem, M. De Smet, et al.. (2007). Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects. Clinical Pharmacology & Therapeutics. 83(2). 293–299. 134 indexed citations
16.
Lai, Eseng, Inge De Lepeleire, Fang Liu, et al.. (2007). Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D2 Receptor Antagonist. Clinical Pharmacology & Therapeutics. 83(6). 840–847. 41 indexed citations
17.
Lai, Eseng, Inge De Lepeleire, Fang Liu, et al.. (2007). Suppression of Niacin-induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1. Clinical Pharmacology & Therapeutics. 81(6). 849–857. 110 indexed citations
18.
Wagner, JA, et al.. (2006). Biomarkers and Surrogate End Points for Fit-for-Purpose Development and Regulatory Evaluation of New Drugs. Clinical Pharmacology & Therapeutics. 81(1). 104–107. 123 indexed citations
19.
Thompson, Marilyn E., Donna L. Valentine, Samuel J. Strada, JA Wagner, & Jonathan G. Scammell. (1994). Transcriptional regulation of secretogranin II and chromogranin B by cyclic AMP in a rat pheochromocytoma cell line.. Molecular Pharmacology. 46(5). 880–889. 19 indexed citations
20.
Reynolds, Ian J., JA Wagner, Solomon H. Snyder, et al.. (1986). Brain voltage-sensitive calcium channel subtypes differentiated by omega-conotoxin fraction GVIA.. Proceedings of the National Academy of Sciences. 83(22). 8804–8807. 267 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ronald Gieschke Breakdown of academic impact, for papers by David Hreniuk Breakdown of academic impact, for papers by Kyung‐Hoon Lee Breakdown of academic impact, for papers by Paola Borgiani Breakdown of academic impact, for papers by Ewa Ehrenborg Breakdown of academic impact, for papers by Anthony G.W. Norden Breakdown of academic impact, for papers by R Stoltz Breakdown of academic impact, for papers by Donna J. Buckley Breakdown of academic impact, for papers by Cinzia Ciccacci Breakdown of academic impact, for papers by Aiping Zhang
Rankless by CCL
2026